GRTX Stock Overview
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Galera Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.15 |
52 Week High | US$3.59 |
52 Week Low | US$0.085 |
Beta | 2.23 |
1 Month Change | -20.05% |
3 Month Change | 7.34% |
1 Year Change | -94.27% |
3 Year Change | -98.26% |
5 Year Change | n/a |
Change since IPO | -98.72% |
Recent News & Updates
Recent updates
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Feb 15Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Oct 25Galera Therapeutics appoints chief medical officer
Sep 01Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment
Jun 29Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Jun 15Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
Mar 23Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 24Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher
Dec 24Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Nov 04Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
Aug 05Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 17Galera Therapeutics EPS beats by $0.08
Nov 10Shareholder Returns
GRTX | US Biotechs | US Market | |
---|---|---|---|
7D | -36.7% | 0.9% | 0.4% |
1Y | -94.3% | 10.3% | 28.8% |
Return vs Industry: GRTX underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: GRTX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
GRTX volatility | |
---|---|
GRTX Average Weekly Movement | 20.1% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRTX's share price has been volatile over the past 3 months.
Volatility Over Time: GRTX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 31 | J. Sorensen | https://www.galeratx.com |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
Galera Therapeutics, Inc. Fundamentals Summary
GRTX fundamental statistics | |
---|---|
Market cap | US$8.35m |
Earnings (TTM) | -US$69.68m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs GRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GRTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$69.68m |
Earnings | -US$69.68m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.28 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -118.8% |
How did GRTX perform over the long term?
See historical performance and comparison